Articles related to GENE THERAPY

“When it is proven to be safe, durable, deliverable in young children, and clearly improves long-term communication outcomes, not just hearing thresholds, then it becomes a routine referral.” — Julie Wei, MD, Akron Children’s Hospital

“Now that we have a treatment for genetic deafness, our hope is that this will spur universal genetic testing in all kids with hearing loss.” —Lawrence Lustig, MD, CHORD study investigator

Valoctocogene roxaparvovec gene therapy demonstrates long-term efficacy in reducing bleeding episodes and factor VIII use in patients with severe hemophilia A, potentially changing the treatment landscape for this condition.

Exa-cel’s success in the CLIMB THAL-111 trial represents a transformative approach to treating β-thalassemia, eliminating dependency on transfusions and underscoring the potential of gene editing in hematological disorders.

Healthcare professionals are navigating a complex dialogue on COVID-19 vaccine shedding, underscored by FDA acknowledgments and Pfizer protocols that hint at the nuanced risks of gene therapy product exposure.

The comparative modeling analysis of gene therapy for sickle cell disease underscores its potential cost-effectiveness and value in enhancing patient quality of life. With estimated ICERs significantly varying under different perspectives, the findings advocate for a nuanced approach to assessing novel therapies within the broader healthcare landscape.